Arvinas develops medicines based on PROTAC targeted protein degradation, which tags disease-causing proteins for destruction by the cell’s own disposal system. It brought forward the first FDA-approved PROTAC, vepdegestrant (VEPPANU), for certain ER+/HER2- ESR1-mutated advanced or metastatic breast cancers, and continues to advance degraders in oncology and neurology. The platform aims at proteins that are hard to drug with conventional small molecules.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 188.8 | — | 82.9 | — |
| Q2 2025 | 22.4 | — | -61.2 | — |
| Q3 2025 | 41.9 | — | -35.1 | — |
| Q4 2025 | 9.5 | — | -67.4 | — |
| Q1 2026 | 15.6 | -91.7% | -57.6 | -169.5% |
| Q2 2026 | 249.7 | 1,014.7% | 169.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Johnson Outdoors Inc. (JOUT), Industrial Logistics Properties Trust (ILPT), Allogene Therapeutics, Inc. (ALLO), Consolidated Water Co. Ltd. (CWCO), Tilray Brands, Inc. (TLRY), Oculis Holding AG (OCS)